HepCBC Mission Statement
HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.
Hot Off The Press!
The Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score was highly predictive of hepatocellular carcinoma (HCC) recurrence risk following liver transplantation, according to a study published in JAMA Oncology.1 Although various factors are associated with increased risk of HCC recurrence after liver transplantation, no reliable risk score has been established to determine the individual risk for HCC recurrence. Researchers therefore de
Denying patients access to something with such clear benefits is immoral, it's illegal, and it shouldn't be happening." — Julia Shaw, health care policy analyst in the Office of the Health Care Advocate. While this story is from Vermont in the USA the same holds true for Canada. Canada's policy restricting access is immoral and illegal. Health advocates are challenging a Vermont Medicaid policy that has restricted curative treatment for hepatitis C only
Friday, December 2, 2016 News Recap Top of the news is that both Canada (Information Update – Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B) and Europe (EU health regulator warns some hep C drugs could reactivate hep B) are warning of the possibility of HBV reactivation from HCV DAA therapy. The first warnings came out in April 2016 at EASL and then the US FDA issued warnings in October 2016. In a press release, Health C...
The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments. The latest health warning covers some of the top-selling products in the multi-billion dollar hepatitis C market, including Sovaldi, Exviera, Viekirax, Olysio and Daklinza. These drugs cure well over 90 percent of pati
OTTAWA, Dec. 1, 2016 /CNW/ - A recent Health Canada safety review found that patients infected with both hepatitis B and hepatitis C viruses who are being treated for hepatitis C with direct-acting antivirals may experience a reactivation of their hepatitis B. Hepatitis B reactivation is the return of an active hepatitis B infection, which can lead to serious complications such as liver failure. As a result, Health Canada is working with manufacturers to